- Home
- ANVS
ANVS
Annovis Bio Inc.
as 11-18-2025 3:42pm EST
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 53.3M | IPO Year: | 2020 |
| Target Price: | $13.50 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $7.52 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Annovis Bio Inc. (ANVS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hoffman Michael B | ANVS | Director | Nov 14 '25 | Buy | $2.11 | 15,000 | $31,650.00 | 2,470,539 | |
| Maccecchini Maria-Luisa | ANVS | President & CEO | Oct 28 '25 | Buy | $2.05 | 97,561 | $200,000.05 | 1,212,020 | |
| Hoffman Michael B | ANVS | Director | Oct 28 '25 | Buy | $2.05 | 975,610 | $2,000,000.50 | 2,470,539 |
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
GlobeNewswire
2 days ago
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
MT Newswires
7 days ago
Annovis Bio Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
GlobeNewswire
7 days ago
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
GlobeNewswire
13 days ago
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
GlobeNewswire
a month ago
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
MT Newswires
a month ago
Annovis Bio to Raise $6 Million in Registered Direct Offering; Shares Fall
GlobeNewswire
a month ago
Annovis Announces $6 Million Registered Direct Offering of Common Stock
Compare ANVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANVS Annovis Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.